Recombinant novel coronavirus protein vaccine (CHO cells)

BIOLOGICAL3 trials

Sponsors

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Conditions

COVID-19Coronavirus

Phase 3

A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell)

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.COVID-19

Start: 2022-11-07End: 2023-09-30Target: 400Updated: 2022-11-15

Unknown Phase

Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

CompletedNCT05850507

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Coronavirus

Start: 2023-03-17End: 2024-03-20Updated: 2024-05-13

Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Coronavirus

Start: 2023-09-20End: 2024-06-30Target: 160Updated: 2023-09-06

Related Papers

Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.

2024-04-0316 citations